
Your Feed
What should individuals who are starting treatment know about blood clots?
What are we learning about the optimal duration of bispecific antibody therapy?
What is the role of radiation therapy in the treatment of newly diagnosed DLBCL patients?
Should T-cell be profiled for fitness (not exhausted) prior to using T cell-redirecting?
When is it appropriate to use stem cell transplant for newly diagnosed DLBCL patients? What are the eligibility criteria?
When are bispecific antibodies and CAR T-cell therapy used for DLBCL, and how might that change in the future?
What treatments are available for patients with relapsed refractory myeloma who have received at least two prior lines of therapy but less than 4 lines of therapy?
What is the difference between phenotype and genotype?
BETA - What is the role of the care partner once the patient returns home?
BETA - What are the main side effects of CAR T-cell therapy?









